Quest Pharmatech Inc
- LAST PRICE0.0400
- TODAY'S CHANGE (%)0.0050 (14.2857%)
- Bid / Lots0.0300/ 50
- Ask / Lots0.0400/ 103
- Open / Previous Close0.0400 / 0.0350
- Day Range
- 52 Week Range
- Volume54,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QPT |
|---|---|---|
| 09:32 ET | 2000 | 0.04 |
| 09:57 ET | 2000 | 0.04 |
| 11:05 ET | 50000 | 0.04 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Quest Pharmatech Inc | 5.9M | 0.5x | --- |
GeneTether Therapeutics Inc | 3.9M | -5.2x | --- |
Glow Lifetech Corp | 6.7M | -1.6x | --- |
Rakovina Therapeutics Inc | 5.0M | -1.4x | --- |
XORTX Therapeutics Inc | 5.0M | -35.1x | --- |
Awakn Life Sciences Corp | 5.0M | -1.3x | --- |
Company Information
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Contact Information
- Headquarters
- 4342 97 StreetEDMONTON, AB, Canada T6E 5R9
- Phone
- 780-448-1400
- Fax
- 780-448-1400
Executives
- Independent Chairman of the Board
- J. Mark Lievonen
- Chief Executive Officer, Director
- Ragupathy Madiyalakan
- Chief Financial Officer
- Pierre Vermette
- Independent Director
- Bradley Glass
- Independent Director
- Jeffrey Shon
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 169.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.35 |
EPS | $0.08 |
Book Value | $0.14 |
P/E Ratio | 0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 0.4x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
